« Zurück
Startseite /
Pamidronate (disodium)

Pamidronate (disodium)

ArtNr	HY-B0012A-5mg
Hersteller	MedChem Express
CAS-Nr.	57248-88-1
Menge	5 mg
Quantity options	100 mg 10 mg 1 ea 200 mg 500 mg 50 mg 5 mg
Kategorie	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Lymphatic System Cancer Bone Cancer
Typ	Inhibitors
Specific against	other
Purity	98.0
Citations	[1]Ashton JA, et al. Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cellsfrom dogs. Am J Vet Res. 2005 May;66(5):885-91. [2]Xu Y, et al. Pamidronate Disodium Leads to Bone Necrosis via Suppression of Wnt/β-Catenin Signaling in Human Bone Marrow Mesenchymal Stem Cells In Vitro. J Oral Maxillofac Surg. 2017 Mar 22. [3]Lv Y, et al. Effects of pamidronate disodium on the loss of osteoarthritic subchondral bone and the expression of cartilaginous and subchondral osteoprotegerin and RANKL in rabbits. BMC Musculoskelet Disord. 2014 Nov 6;15:370. [4]Kovacs R, et al. The synthesis of pamidronic derivatives in different solvents: An optimization and a mechanistic study[J]. Heteroatom Chemistry, 2014, 25(3): 186-193.
Smiles	OP(C(O)(P(O)(O[Na])=O)CCN)(O[Na])=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CGP 23339A
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Metabolism-protein/nucleotide metabolism
Manufacturer - Targets	RANKL/RANK ; Toll-like Receptor (TLR); Wnt; β-catenin
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	279.03
Product Description	Pamidronate disodium, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronate disodium significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronate disodium can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma[1][2][3][4].
Manufacturer - Research Area	Cancer; Metabolic Disease; Inflammation/Immunology
Solubility	H2O : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Immunology/Inflammation; NF-κB; Stem Cell/Wnt
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-B0012A-5mg-safety-datasheet.pdf